SCHEMBL770041

SCHEMBL770041

CCOC(=O)CCCC(=O)N1CCCC2CCCC=C21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NOTUM Q6P988 1/20 0.39
ALDH1A1 P00352 6/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 4/20 0.38
TSHR P16473 4/20 0.38
HRH3 Q9Y5N1 1/20 0.37
SMYD3 Q9H7B4 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NAMPT P43490 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770616 0.87 MAPT (0.36) RAB9ANPC1TSHRSMN1; SMN2HPGD
SCHEMBL770581 0.86 ALOX15 (0.37) RAB9ANOTUMALDH1A1ALOX15NPC1
SCHEMBL771018 0.85 ALDH1A1 (0.40) NOTUMALDH1A1TSHRHRH3CYP3A4
SCHEMBL770945 0.85 NAAA (0.36) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL772447 0.84 ALDH1A1 (0.41) RAB9AL3MBTL1ALDH1A1ALOX15NPC1
SCHEMBL770712 0.83 LMNA (0.33) TSHRMEN1KMT2APOLBLMNA
SCHEMBL770693 0.82 ITGB3 (0.35) ALDH1A1TSHRHRH3SMN1; SMN2MEN1
SCHEMBL770710 0.81 TP53 (0.33) TSHRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL15224149 0.80 FFAR4 (0.37) TSHRHRH3
SCHEMBL770742 0.80 ITGB3 (0.33) TSHRSMYD3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2187/4885L3MBTL1 4097/4885NOTUM 369/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2217/4885L3MBTL1 4090/4885NOTUM 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.